Objective We tested the hypothesis that a c-reactive protein (CRP) and ferritin based systemic inflammation contingency table can track mortality risk in pediatric severe sepsis. Design Prospective cohort study Setting Tertiary Pediatric Intensive Care Unit Patients Children with 100 separate admission episodes of severe sepsis were enrolled. Interventions Blood samples were attained on day two of sepsis and bi-weekly for biomarker batch analysis. A 2 × 2 contingency table using CRP and ferritin thresholds was developed. Measurements and Main Results A CRP of 4.08 mg/dL and a ferritin of 1,980 ng/mL were found to be optimal cutoffs for outcome prediction at first sampling (n = 100) using the Youden Index. PICU mortality was increased in the ‘High risk’ CRP ≥ 4.08 mg/dL and Ferritin ≥ 1,980 ng/mL category (6/13, 46.15%) compared to the ‘Intermediate risk’ CRP ≥ 4.08 mg/dL and Ferritin < 1,980 ng/mL or CRP < 4.08 mg/dL and Ferritin ≥ 1,980 ng/mL categories (2/43, 4.65%), and the ‘Low risk’ CRP < 4.08 mg/dL and Ferritin < 1,980 ng/mL category (0/44, 0%) (OR 36.43 [95% CI: 6.16–215.21]). The ‘High risk’ category was also associated with the development of Immunoparalysis (OR 4.47 [95% CI 1.34–14.96]) and Macrophage Activation Syndrome (OR 24.20 [95% CI 5.50–106.54]). Sixty three children underwent sequential blood sampling; those who were initially in the ‘Low risk’ category (n = 24) and those who subsequently migrated to (n =19) to the ‘Low risk’ category all survived, whereas those who remained in the ‘At risk’ categories had increased mortality (7/20 = 35%; p < 0.05). Conclusions A CRP and ferritin based contingency table effectively assessed mortality risk. Reduction in systemic inflammation below a combined threshold CRP of 4.08 mg/dL and ferritin of 1,980 ng / mL appeared to be a desired response in children with severe sepsis.

Background: Precision health calls for collecting and analyzing large amounts of data to capture an individual's unique behavior, lifestyle, genetics, and environmental context. The diffusion of digital tools has led to a significant growth of patient generated health data (PGHD), defined as health-related data created, gathered or inferred by or from patients and for which the patient controls data collection and data sharing. Purpose:We assessed the current evidence of the impact of PGHD use in clinical practice and provide recommendations for the formal integration of PGHD in clinical care. Methods:We searched PubMed, Ovid, Embase, CINAHL, Web of Science, and Scopus up to May 2018. Inclusion criteria were applied and four reviewers screened titles and abstracts and consequently full articles.Findings: Our systematic literature review identified 21 studies that examined the use of PGHD in clinical settings. Integration of PGHD into electronic records was extremely limited, and decision support capabilities were for the most part basic.Discussion: PGHD and other types of patient-reported data will be part of the health care system narrative and we must continue efforts to understand its impact on health outcomes, costs, and patient satisfaction. Nursing scientists need to lead the process of defining the role of PGHD in the era of precision health.

No abstract

The 91% to 98% clinician compliance indicates eProtocol-insulin is an exportable instrument that can establish a replicable experimental method for clinical trials of blood glucose management in critically ill adults. Control of blood glucose was better with eProtocol-insulin than with a simple clinical guideline or a paper-based protocol.